insulin glulisine · Apidra

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Diabetes mellitus requiring insulin therapy
Product first approved 2009PMDA
EU
  • Treatment of adults, adolescents and children, six years or older with diabetes mellitus
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Type 1 Diabetes
NCT00115570 · Sanofi
2005-04 – 2006-11 · Diabetes Mellitus, Insulin-Dependent
What this study did
NCT00046150 · Sanofi
2002-05 – 2002-12 · Diabetes, Type I
What this study did
Type 2 Diabetes
NCT03529123 · Sanofi
2018-06-19 – 2019-11-25 · Type 2 Diabetes Mellitus
What this study did
NCT00174642 · Sanofi
2004-12 – 2008-12 · Diabetes Mellitus, Type 2
What this study did
NCT00272064 · Sanofi
2005-10 – 2008-05 · Diabetes Mellitus, Type 2
What this study did
NCT00135083 · Sanofi
2004-08 – 2007-11 · Diabetes Mellitus, Type 2
What this study did
NCT00174668 · Sanofi
2004-11 – 2007-11 · Diabetes Mellitus, Type 2
What this study did
NCT00562133 · IKFE Institute for Clinical Research and Development
2006-12 – 2007-03 · Diabetes Mellitus
What this study did
NCT00272012 · Sanofi
2004-07 – 2006-09 · Diabetes Mellitus Type 2
What this study did
Other / comorbidity
NCT00670228 · Sanofi
2008-04 – 2009-11 · AMI
What this study did
NCT00271284 · Sanofi
2005-10 – 2008-09 · Diabetes Mellitus, Type 1
What this study did
NCT00467376 · Sanofi
2007-01 – 2008-06 · Diabetes Mellitus
What this study did
NCT00397553 · Sanofi
2005-01 – 2007-12 · Diabetes Mellitus, Type 1
What this study did
Phase 2 (5)
Type 1 Diabetes
NCT01194245 · Halozyme Therapeutics
2010-08 – 2011-08 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01194258 · Halozyme Therapeutics
2010-08 – 2011-08 · Diabetes Mellitus, Type II
What this study did
Other / comorbidity
NCT02503501 · HealthPartners Institute
2015-09-28 – 2019-02-15 · Mild Cognitive Impairment, Alzheimer's Disease (AD)
What this study did
NCT01662921 · Sansum Diabetes Research Institute
2013-04 – 2015-08-31 · Diabetes During Pregnancy
What this study did
NCT01436045 · HealthPartners Institute
2011-09 – 2013-06 · Alzheimer's Disease
What this study did
Phase 1 (11)
Type 1 Diabetes
NCT00368394 · Sanofi
started 2004-01 · Diabetes Mellitus, Type I
What this study did
NCT00297583 · Sanofi
2004-04 – 2004-05 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT00824668 · Novo Nordisk A/S
2007-08 – 2007-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00310297 · Sanofi
2004-11 – 2004-12 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT02432716 · HealthPartners Institute
2015-04 – 2018-10-18 · Down Syndrome
What this study did
NCT00979875 · Halozyme Therapeutics
2009-09 – 2010-05 · Healthy
What this study did
NCT00969592 · Profil Institut für Stoffwechselforschung GmbH
2007-11 – 2008-06 · Diabetes
What this study did
NCT00311077 · Sanofi
2004-04 – 2004-10 · Diabetes Mellitus
What this study did
NCT00290043 · Sanofi
2001-12 – 2002-03 · Diabetes Mellitus Type 1
What this study did
Phase 4 (36)
Type 1 Diabetes
NCT03328845 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2017-01-20 – 2021-11-20 · Type 1 Diabetes Mellitus
What this study did
NCT02914886 · Kinderkrankenhaus auf der Bult
2016-09 – 2019-04 · Type 1 Diabetes, Lipoatrophy
What this study did
NCT03260868 · Sanofi
2017-09-19 – 2018-11-22 · Type 1 Diabetes Mellitus
What this study did
NCT02685449 · Medical University of Warsaw
2016-02 – 2018-08 · Diabetes type1
What this study did
NCT02276859 · Medical University of Warsaw
2014-10 – 2015-09 · Type 1 Diabetes
What this study did
NCT01204593 · Sanofi
2010-11 – 2013-01 · Diabetes Mellitus, Type 1
What this study did
NCT01678235 · Medical University of Warsaw
2011-09 – 2012-09 · Type 1 Diabetes Mellitus
What this study did
NCT00913497 · Corewell Health West
2009-06 – 2012-01 · Type 1 Diabetes Mellitus
What this study did
NCT00964574 · Sanofi
2009-07 – 2010-07 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT03359837 · Sanofi
2018-01-20 – 2020-06-29 · Type 2 Diabetes Mellitus
What this study did
NCT02048189 · Centre Hospitalier Universitaire Dijon
2012-03-08 – 2015-02-26 · Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy
What this study did
NCT01594060 · HaEmek Medical Center, Israel
2012-06 – 2014-10 · Diabetes Mellitus Type 2
What this study did
NCT02333851 · Hospital Universitario Central de Asturias
2013-06 – 2014-02 · Type 2 Diabetes Mellitus
What this study did
NCT00596687 · Emory University
2007-12 – 2013-07 · Type 2 Diabetes, Inpatient Hyperglycemia
What this study did
NCT00965549 · Sanofi
2009-07 – 2012-12 · Diabetes Mellitus, Type 2
What this study did
NCT01500850 · ikfe-CRO GmbH
2011-10 – 2012-10 · Insulin-requiring Type 2 Diabetes Mellitus
What this study did
NCT01079364 · Sanofi
2010-01 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01203111 · Sanofi
2010-12 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01417897 · ikfe-CRO GmbH
2011-09 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT01121835 · Sanofi
2010-02 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT01013571 · Sanofi
2009-10 – 2012-01 · Diabetes Mellitus, Type 2
What this study did
NCT00384085 · Sanofi
2006-05 – 2010-03 · Diabetes Mellitus, Type 2
What this study did
NCT00360698 · Sanofi
2006-07 – 2008-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04124302 · Medical University of Warsaw
2019-10-01 – 2024-12-31 · Diabetes Mellitus, Type 1
What this study did
NCT04019821 · Medical University of Warsaw
2020-01-01 – 2023-04-01 · Diabetes Mellitus, Type 1
What this study did
NCT01131052 · Guillermo Umpierrez
2011-03 – 2013-12 · Diabetes, Hyperglycemia
What this study did
NCT01202474 · Sanofi
2011-05 – 2012-10 · Diabetes Mellitus, Type 1
What this study did
NCT00489190 · Sanofi
started 2005-08 · Diabetes Mellitus, Type 1
What this study did
NCT00539448 · Sanofi
2007-04 – 2008-12 · Diabetes Mellitus, Type 1
What this study did
NCT00526513 · Sanofi
2007-07 – 2008-05 · Diabetes Mellitus
What this study did
Early phase / not applicable (6)
Type 1 Diabetes
NCT01621776 · University of Florida
2011-06 – 2012-08 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT00528918 · Carl T. Hayden VA Medical Center
2007-06 – 2011-05 · Diabetes Mellitus, Type II
What this study did
Other / comorbidity
NCT01855243 · Cairo University
2010-03 – 2014-06 · Diabetes Mellitus (DM)
What this study did
NCT00467636 · The Royal Bournemouth Hospital
2007-07 – 2009-05 · Chronic Obstructive Pulmonary Disease, Hyperglycemia
What this study did
Used as active comparator (4)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Type 1 Diabetes
NCT07070752 · Geropharm
2023-04-14 – 2023-11-28 · Type 1 Diabetes Mellitis
What this study did
Type 2 Diabetes
Phase 4 (2)
Type 2 Diabetes
NCT00467649 · AstraZeneca
2007-05 – 2008-04 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT02276196 · Amsterdam UMC, location VUmc
2014-09 – 2016-04 · Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus, Glucagon-Like Peptide 1
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Type 2 Diabetes
NCT01081938 · Sanofi
2010-02 – 2011-02 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Glulisine (Apidra): this drugApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.